Ipilimumab Trademark Details

Ipilimumab was registered on Tuesday, September 1, 2009 and is currently owned by Bristol-Myers Squibb Company under the registration number 3677086 . This mark is dead with a status of Cancelled - Section 8. The last case file activity for this mark occured 6 years ago on Friday, April 8, 2016, according to the United State Patent & Trademark Office
Word Mark Ipilimumab
Status Dead Registered 710 — Cancelled - Section 8

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77273787
Registration Number 3677086
Status Date Friday, April 8, 2016
Filing Date Friday, April 8, 2016
Registration Date Tuesday, September 1, 2009
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154

Case File Statements

Indication of Colors Color is not claimed as a feature of the mark.
Disclaimer with Predetermined Text "Ipilimumab"
Description of Mark The mark consists of a stylized double helix and cells and the word "IPILIMUMAB" in stylized lettering.
Goods & Services Medical and Scientific Research, Namely, Conducting Clinical Trials Relating to Pharmaceutical Preparations for Human Use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 2 — Sec. 8 – Entire Registration
Status Date Friday, April 8, 2016
First Use Anywhere Saturday, May 31, 2008
First Use In Commerce Saturday, May 31, 2008
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.